Homeostasis of peripheral FoxP3+ CD4+ regulatory T cells in patients with early and late stage breast cancer

Cancer Immunology, Immunotherapy

Volumn 59, Issue 4, 2010, Pages 599-607

  Rech, Andrew J ^a   Mick, Rosemarie ^b   Kaplan, David E ^c,d   Chang, Kyong Mi ^c,d   Domchek, Susan M ^c   Vonderheide, Robert H ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Breast cancer; Clinical trial; Regulatory T cell

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DOXORUBICIN; GAMMA INTERFERON; TAXANE DERIVATIVE; TRANSCRIPTION FACTOR FOXP3; CYTOTOXIC T-LYMPHOCYTE ANTIGEN 4; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; LEUKOCYTE ANTIGEN;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER STAGING; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; METASTASIS; PRIORITY JOURNAL; REGULATORY MECHANISM; REGULATORY T LYMPHOCYTE; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; COMPARATIVE STUDY; FEMALE; FLOW CYTOMETRY; HOMEOSTASIS; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PROGNOSIS; SECRETION;

ANTIGENS, CD; BREAST NEOPLASMS; CD4-POSITIVE T-LYMPHOCYTES; CHEMOTHERAPY, ADJUVANT; FEMALE; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; HOMEOSTASIS; HUMANS; IMMUNE TOLERANCE; INTERFERON-GAMMA; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; T-LYMPHOCYTES, REGULATORY;

EID: 77449101222     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-009-0780-x     Document Type: Article

References (44)

1. Baecher-Allan C, Viglietta V, Hafler DA (2004) Human CD4+ CD25+ regulatory T cells. Semin Immunol 16:89-98 (Pubitemid 38234760)
2. Shevach EM (2006) From vanilla to 28 flavors: multiple varieties of T regulatory cells. Immunity 25:195-201 (Pubitemid 44224153)
3. Zou W (2006) Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 6:295-307
4. Sakaguchi S, Yamaguchi T, Nomura T, Ono M (2008) Regulatory T cells and immune tolerance. Cell 133:775-787
5. Camara NO, Sebille F, Lechler RI (2003) Human CD4+ CD25+ regulatory cells have marked and sustained effects on CD8+ T cell activation. Eur J Immunol 33:3473-3483
6. Thornton AM, Shevach EM (2000) Suppressor effector function of CD4+ CD25+ immunoregulatory T cells is antigen nonspecific. J Immunol 164:183-190
7. WooEY,ChuCS,GoletzTJ,SchliengerK,YehHetal(2001)RegulatoryCD4(+)CD25(+) Tcellsintumorsfrom,patientswithearly-stagenon-smallcelllungcancerandlate- stageovariancancer.CancerRes61:4766-4772(Pubitemid32691889)
8. LiyanageUK,MooreTT,JooHG,TanakaY,HerrmannVetal(2002) PrevalenceofregulatoryTcellsisincreasedinperipheralbloodandtumormicroenvironm entofpatientswithpancreasorbreastadenocarcinoma.JImmunol169:2756- 2761(Pubitemid34921025)
9. WolfAM,WolfD,SteurerM,GastlG,GunsiliusEetal(2003) IncreaseofregulatoryTcellsintheperipheralbloodofcancerpatients.ClinCancerRes9: 606-612(Pubitemid36182591)
10. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P et al (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942-949
11. Khattri R, Cox T, Yasayko SA, Ramsdell F (2003) An essential role for Scurfin in CD4+ CD25+ T regulatory cells. Nat Immunol 4:337-342
12. Wildin RS, Ramsdell F, Peake J, Faravelli F, Casanova JL et al (2001) X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet 27:18-20 (Pubitemid 32044512)
13. Gavin MA, Torgerson TR, Houston E, DeRoos P, Ho WY et al (2006) Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development. Proc Natl Acad Sci USA 103:6659-6664
14. Ahmadzadeh M, Antony PA, Rosenberg SA (2007) IL-2 and IL15 each mediate de novo induction of FOXP3 expression in human tumor antigen-specific CD8 T cells. J Immunother 30:294-302 (Pubitemid 46586645)
15. Wang J, Ioan-Facsinay A, van der Voort EI, Huizinga TW, Toes RE (2007) Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells. Eur J Immunol 37:129-138 (Pubitemid 46128793)
16. DiGiacomoA,NorthRJ(1986)Tcellsuppressorsofantitumorimmunity: theproductionofLy-1-, 2+suppressorsofdelayedsensitivityprecedestheproductionofsuppressorsofprotect iveimmunity.JExpMed164:1179-1192(Pubitemid16031615)
17. Turk MJ, Guevara-Patino JA, Rizzuto GA, Engelhorn ME, Sakaguchi S et al (2004) Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med 200:771-782
18. Ercolini AM, Ladle BH, Manning EA, Pfannenstiel LW, Armstrong TD et al (2005) Recruitment of latent pools of highavidity CD8(+) T cells to the antitumor immune response. J Exp Med 201:1591-1602
19. OnizukaS,TawaraI,ShimizuJ,SakaguchiS,FujitaTetal(1999) Tumorrejectionbyinvivoadministrationofanti-CD25(interleukin2receptoralpha) monoclonalantibody.CancerRes59:3128-3133(Pubitemid29316012)
20. Shimizu J, Yamazaki S, Sakaguchi S (1999) Induction of tumor immunity by removing CD25+ CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 163:5211-5218
21. Sutmuller RP, van Duivenvoorde LM, van Elsas A, Schumacher TN, Wildenberg ME et al (2001) Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 194:823-832
22. Dannull J, Su Z, Rizzieri D, Yang BK, Coleman D et al (2005) Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 115:3623-3633 (Pubitemid 43121851)
23. AttiaP,MakerAV,HaworthLR,Rogers-FreezerL,RosenbergSA(2005) InabilityofafusionproteinofIL-2anddiphtheriatoxin(DenileukinDiftitox,DAB389IL-2, ONTAK)-eliminateregulatoryTlymphocytesinpatientswithmelanoma.JImmunother28: 582-592(Pubitemid41533092)
24. Ruter J, Barnett BG, Kryczek I, Brumlike MJ, Daniel BJ et al (2006) Manipulating T regulatory cells in cancer immunotherapy. Exp Rev Derm 1:589-597
25. Mahnke K, Schonfeld K, Fondel S, Ring S, Karakhanova S et al (2007) Depletion of CD4+ CD25+ human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro. Int J Cancer 120:2723-2733 (Pubitemid 46651297)
26. Powell DJ Jr, Attia P, Ghetie V, Schindler J, Vitetta ES et al (2008) Partial reduction of human FoxP3+ CD4 T cells in vivo after CD25-directed recombinant immunotoxin administration. J Immunother 31:189-198
27. Rasku MA, Clem AL, Telang S, Taft B, Gettings K et al (2008) Transient T cell depletion causes regression of melanoma metastases. J Transl Med 6:12 (Pubitemid 351597459)
28. Morse MA, Hobeika AC, Osada T, Serra D, Niedzwiecki D et al (2008) Depletion of human regulatory T cells specifically enhances antigen specific immune responses to cancer vaccines. Blood 112:610-618
29. Bates GJ, Fox SB, Han C, Leek RD, Garcia JF et al (2006) Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 24:5373-5380 (Pubitemid 46623168)
30. Wolf AM, Rumpold H, Wolf D, Gastl G, Reimer D et al (2007) Role of forkhead box protein 3 expression in invasive breast cancer. J Clin Oncol 25:4499-4500 (Pubitemid 350013859)
31. Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP et al (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21:1431-1439
32. Jones SE, Savin MA, Holmes FA, O'Shaughnessy JA, Blum. JL et al (2006) Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 24:5381-5387
33. Golovina TN, Mikheeva T, Suhoski MM, Aqui NA, Tai VC et al (2008) CD28 costimulation is essential for human T regulatory expansion and function. J Immunol 181:2855-2868
34. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Statist Soc B 57:289-300
35. Pillai V, Karandikar NJ (2008) Attack on the clones? Human FOXP3 detection by PCH101, 236A/E7, 206D, and 259D reveals 259.D as the outlier with lower sensitivity. Blood 111:463-464
36. Tran DQ, Ramsey H, Shevach EM (2007) Induction of FOXP3 expression in naive human CD4+ FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-beta dependent but does not confer a regulatory phenotype. Blood 110:2983-2990 (Pubitemid 350006952)
37. Zheng Y, Manzotti CN, Burke F, Dussably L, Qureshi O et al (2008) Acquisition of suppressive function by activated human CD4+ CD25- T cells is associated with the expression of CTLA-4 not FoxP3. J Immunol 181:1683-1691
38. Ahmadzadeh M, Felipe-Silva A, Heemskerk B, Powell DJ Jr, Wunderlich JR et al (2008) FOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanoma lesions. Blood 112:49534960
39. Kryczek I, Liu R, Wang G, Wu K, Shu X et al (2009) FOXP3 defines regulatory T cells in human tumor and autoimmune disease. Cancer Res 69:3995-4000
40. DelongP,CarrollRG,HenryAC,TanakaT,AhmadSetal(2005) RegulatoryTcellsandcytokinesinmalignantpleuraleffusionssecondarytomesotheliom aandcarcinoma.CancerBiolTher4:342-346(Pubitemid41351297)
41. Dejaco C, Duftner C, Schirmer M (2006) Are regulatory T-cells linked with aging? Exp Gerontol 41:339-345
42. Gregg R, Smith CM, Clark FJ, Dunnion D, Khan N et al (2005) The number of human peripheral blood CD4+ CD25high regulatory T cells increases with age. Clin Exp Immunol 140:540-546 (Pubitemid 40813966)
43. Lages CS, Suffia I, Velilla PA, Huang B, Warshaw G et al (2008) Functional regulatory T cells accumulate in aged hosts and promote chronic infectious disease reactivation. J Immunol 181:1835-1848
44. Rech AJ, Vonderheide RH (2009) Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells. Ann N Y Acad Sci 1174:99-106